Review

Key Laboratory of Environmental Medicine & Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, China

‡Authors contributed equally

Shizhi Wang‡

*Author for correspondence:

E-mail Address: shizhiwang2009@seu.edu.cn

https://orcid.org/0000-0002-6083-6753

Key Laboratory of Environmental Medicine & Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, China

‡Authors contributed equally

Search for more papers by this author

Xiuting Li

**Author for correspondence:

E-mail Address: xiutingli2016@yeah.net

Department of Public Health, Jiangsu Health Vocational College, Nanjing, 210000, China

Search for more papers by this author

Published Online:19 Apr 2024https://doi.org/10.2217/epi-2024-0002

View article

Abstract

Cervical cancer (CC) remains one of the most common malignancies among women worldwide, posing a serious threat to women's health. N6-methyladenosine (m⁶A) modification, as the most abundant type of RNA methylation modification, and has been found to play a crucial role in various cancers. Current research suggests a close association between RNA m⁶A modification and the occurrence and progression of CC, encompassing disruptions in m⁶A levels and its regulatory machinery. This review summarizes the current status of m⁶A modification research in CC, explores the mechanisms underlying m⁶A levels and regulators (methyltransferases, demethylases, reader proteins) in CC and examines the application of small-molecule inhibitors of m⁶A regulators in disease treatment. The findings provide new insights into the future treatment of CC.

Tweetable abstract

The m⁶A modification participates in regulating the proliferation, migration, invasion, cell cycle, apoptosis, drug resistance and sensitivity to chemotherapy in cervical cancer cells.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Cao W, Chen HD, Yu YW et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin. Med. J. (Engl) 2021;134(7):783–791. doi:10.1097/CM9.0000000000001474
MedlineGoogle Scholar
2. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
MedlineGoogle Scholar
3. O'Mara TA, Zhao M, Spurdle AB. Meta-analysis of gene expression studies in endometrial cancer identifies gene expression profiles associated with aggressive disease and patient outcome. Sci. Rep. 2016;6:36677. doi:10.1038/srep36677
Google Scholar
4. Coutinho F, Gokhale M, Doran C et al. Characteristics, treatment patterns, and outcomes in patients with high-risk locally advanced cervical cancer. Cancer Treat. Res. Commun. 2024;39:100800. doi:10.1016/j.ctarc.2024.100800
Google Scholar
5. Jiang T, Zhou B, Li YM et al. ALOX12B promotes carcinogenesis in cervical cancer by regulating the PI3K/ERK1 signaling pathway. Oncol. Lett. 2020;20(2):1360–1368. doi:10.3892/ol.2020.11641
CASGoogle Scholar
6. Jiang X, Liu B, Nie Z et al. The role of m⁶A modification in the biological functions and diseases. Signal. Transduct. Target Ther. 2021;6(1):74. doi:10.1038/s41392-020-00450-x
Medline CASGoogle Scholar
7. Shi H, Wei J, He C. Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers. Mol. Cell. 2019;74(4):640–650. doi:10.1016/j.molcel.2019.04.025
Medline CASGoogle Scholar
8. Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc. Natl Acad. Sci. USA 1974;71(10):3971–3975. doi:10.1073/pnas.71.10.3971
Medline CASGoogle Scholar
9. Yang Y, Hsu PJ, Chen YS et al. Dynamic transcriptomic m(6)A decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. 2018;28(6):616–624. doi:10.1038/s41422-018-0040-8
Medline CASGoogle Scholar
10. Du H, Zhao Y, He J et al. YTHDF2 destabilizes m(6)A-containing RNA through direct recruitment of the CCR4-NOT deadenylase complex. Nat. Commun. 2016;7:12626. doi:10.1038/ncomms12626
Medline CASGoogle Scholar
11. Huang H, Weng H, Sun W et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat. Cell Biol. 2018;20(3):285–295. doi:10.1038/s41556-018-0045-z
Medline CASGoogle Scholar
12. Meyer KD, Saletore Y, Zumbo P et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3′-UTRs and near stop codons. Cell 2012;149(7):1635–1646. doi:10.1016/j.cell.2012.05.003
Medline CASGoogle Scholar
13. Liu T, Wei Q, Jin J et al. The m⁶A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res. 2020;48(7):3816–3831. doi:10.1093/nar/gkaa048
Medline CASGoogle Scholar
14. Zhang B, Jiang H, Dong Z et al. The critical roles of m⁶A modification in metabolic abnormality and cardiovascular diseases. Genes Dis. 2021;8(6):746–758. doi:10.1016/j.gendis.2020.07.011
CASGoogle Scholar
15. Chen J, Fang Y, Xu Y et al. Role of m⁶A modification in female infertility and reproductive system diseases. Int. J. Biol. Sci. 2022;18(9):3592–3604. doi:10.7150/ijbs.69771
CASGoogle Scholar
16. Zhang N, Ding C, Zuo Y et al. N6-methyladenosine and neurological diseases. Mol. Neurobiol. 2022;59(3):1925–1937. doi:10.1007/s12035-022-02739-0
CASGoogle Scholar
17. Hu Z, Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med. 2018;7(10):5217–5236. doi:10.1002/cam4.1501
Google Scholar
18. Johnson CA, James D, Marzan A et al. Cervical cancer: an overview of pathophysiology and management. Semin. Oncol. Nurs. 2019;35(2):166–174. doi:10.1016/j.soncn.2019.02.003
MedlineGoogle Scholar
19. Cohen PA, Jhingran A, Oaknin A et al. Cervical cancer. Lancet 2019;393(10167):169–182. doi:10.1016/S0140-6736(18)32470-X
MedlineGoogle Scholar
20. Holowaty P, Miller AB, Rohan T et al. Natural history of dysplasia of the uterine cervix. J. Natl Cancer Inst. 1999;91(3):252–258. doi:10.1093/jnci/91.3.252
CASGoogle Scholar
21. Gopu P, Antony F, Cyriac S et al. Updates on systemic therapy for cervical cancer. Indian J. Med. Res. 2021;154(2):293–302. doi:10.4103/ijmr.IJMR_4454_20
CASGoogle Scholar
22. Lanciano R, Calkins A, Bundy BN et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. J. Clin. Oncol. 2005;23(33):8289–8295. doi:10.1200/JCO.2004.00.0497
CASGoogle Scholar
23. Revathidevi S, Murugan AK, Nakaoka H et al. APOBEC: a molecular driver in cervical cancer pathogenesis. Cancer Lett. 2021;496:104–116. doi:10.1016/j.canlet.2020.10.004
CASGoogle Scholar
24. Fang J, Zhang H, Jin S. Epigenetics and cervical cancer: from pathogenesis to therapy. Tumour Biol. 2014;35(6):5083–5093. doi:10.1007/s13277-014-1737-z
Medline CASGoogle Scholar
25. Oerum S, Meynier V, Catala M et al. A comprehensive review of m⁶A/m⁶Am RNA methyltransferase structures. Nucleic Acids Res. 2021;49(13):7239–7255. doi:10.1093/nar/gkab378
Medline CASGoogle Scholar
26. An Y, Duan H. The role of m⁶A RNA methylation in cancer metabolism. Mol. Cancer 2022;21(1):14. doi:10.1186/s12943-022-01500-4
CASGoogle Scholar
27. Liu ZX, Li LM, Sun HL et al. Link between m⁶A modification and cancers. Front. Bioeng. Biotechnol. 2018;6:89. doi:10.3389/fbioe.2018.00089
MedlineGoogle Scholar
28. Guo J, Zheng J, Zhang H et al. RNA m⁶A methylation regulators in ovarian cancer. Cancer Cell Int. 2021;21(1):609. doi:10.1186/s12935-021-02318-8
Medline CASGoogle Scholar
29. Shen S, Guo J, Lv N et al. RNA m⁶A methylation regulators in endometrial cancer (Review). Int. J. Oncol. 2022;61(6):155. doi:10.3892/ijo.2022.5445
CASGoogle Scholar
30. Zhou H, Yin K, Zhang Y et al. The RNA m⁶A writer METTL14 in cancers: roles, structures, and applications. Biochim. Biophys. Acta Rev. Cancer. 2021;1876(2):188609. doi:10.1016/j.bbcan.2021.188609
Medline CASGoogle Scholar
31. Wang X, Huang J, Zou T et al. Human m(6)A writers: two subunits, 2 roles. RNA Biol. 2017;14(3):300–304. doi:10.1080/15476286.2017.1282025
Google Scholar
32. Wang T, Kong S, Tao M et al. The potential role of RNA N6-methyladenosine in cancer progression. Mol. Cancer 2020;19(1):88. doi:10.1186/s12943-020-01204-7
Medline CASGoogle Scholar
33. Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat. Rev. Mol. Cell Biol. 2019;20(10):608–624. doi:10.1038/s41580-019-0168-5
Medline CASGoogle Scholar
34. Ping XL, Sun BF, Wang L et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014;24(2):177–189. doi:10.1038/cr.2014.3
Medline CASGoogle Scholar
35. Yue Y, Liu J, Cui X et al. VIRMA mediates preferential m(6)A mRNA methylation in 3′-UTR and near stop codon and associates with alternative polyadenylation. Cell Discov. 2018;4:10. doi:10.1038/s41421-018-0019-0
MedlineGoogle Scholar
36. Garcias Morales D, Reyes JL. A birds'-eye view of the activity and specificity of the mRNA m(6) A methyltransferase complex. Wiley Interdiscip. Rev. RNA 2021;12(1):e1618. doi:10.1002/wrna.1618
Google Scholar
37. Patil DP, Chen CK, Pickering BF et al. m(6)A RNA methylation promotes XIST-mediated transcriptional repression. Nature 2016;537(7620):369–373. doi:10.1038/nature19342
Medline CASGoogle Scholar
38. Bawankar P, Lence T, Paolantoni C et al. Hakai is required for stabilization of core components of the m(6)A mRNA methylation machinery. Nat. Commun. 2021;12(1):3778. doi:10.1038/s41467-021-23892-5
Medline CASGoogle Scholar
39. Horiuchi K, Kawamura T, Iwanari H et al. Identification of Wilms' tumor 1-associating protein complex and its role in alternative splicing and the cell cycle. J. Biol. Chem. 2013;288(46):33292–33302. doi:10.1074/jbc.M113.500397
Medline CASGoogle Scholar
40. Wen J, Lv R, Ma H et al. Zc3h13 regulates nuclear RNA m(6)A methylation and mouse embryonic stem cell self-renewal. Mol. Cell 2018;69(6):1028–1038.e6. doi:10.1016/j.molcel.2018.02.015
Medline CASGoogle Scholar
41. Knuckles P, Lence T, Haussmann IU et al. Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the m(6)A machinery component Wtap/Fl(2)d. Genes Dev. 2018;32(5–6):415–429. doi:10.1101/gad.309146.117
Medline CASGoogle Scholar
42. Sun T, Wu R, Ming L. The role of m⁶A RNA methylation in cancer. Biomed. Pharmacother. 2019;112:108613. doi:10.1016/j.biopha.2019.108613
Medline CASGoogle Scholar
43. Xiao MZ, Liu JM, Xian CL et al. Therapeutic potential of ALKB homologs for cardiovascular disease. Biomed. Pharmacother. 2020;131:110645. doi:10.1016/j.biopha.2020.110645
CASGoogle Scholar
44. Fedeles BI, Singh V, Delaney JC et al. The AlkB family of Fe(II)/alpha-ketoglutarate-dependent dioxygenases: repairing nucleic acid alkylation damage and beyond. J. Biol. Chem. 2015;290(34):20734–20742. doi:10.1074/jbc.R115.656462
Medline CASGoogle Scholar
45. Jia G, Fu Y, Zhao X et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat. Chem. Biol. 2011;7(12):885–887. doi:10.1038/nchembio.687
Medline CASGoogle Scholar
46. Li Y, Su R, Deng X et al. FTO in cancer: functions, molecular mechanisms, and therapeutic implications. Trends Cancer 2022;8(7):598–614. doi:10.1016/j.trecan.2022.02.010
Google Scholar
47. Wei C, Wang B, Peng D et al. Pan-cancer analysis shows that ALKBH5 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including gliomas. Front. Immunol. 2022;13:849592. doi:10.3389/fimmu.2022.849592
Medline CASGoogle Scholar
48. Wei J, Liu F, Lu Z et al. Differential m(6)A, m(6)A(m), and m(1)A demethylation mediated by FTO in the cell nucleus and cytoplasm. Mol. Cell 2018;71(6):973–985.e5. doi:10.1016/j.molcel.2018.08.011
Medline CASGoogle Scholar
49. Zheng G, Dahl JA, Niu Y et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol. Cell 2013;49(1):18–29. doi:10.1016/j.molcel.2012.10.015
Medline CASGoogle Scholar
50. Xu Y, Zhang W, Shen F et al. YTH domain proteins: a family of m(6)A readers in cancer progression. Front. Oncol. 2021;11:629560. doi:10.3389/fonc.2021.629560
CASGoogle Scholar
51. Wang X, Zhao BS, Roundtree IA et al. N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell 2015;161(6):1388–1399. doi:10.1016/j.cell.2015.05.014
Medline CASGoogle Scholar
52. Wang X, Lu Z, Gomez A et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature 2014;505(7481):117–120. doi:10.1038/nature12730
MedlineGoogle Scholar
53. Li A, Chen YS, Ping XL et al. Cytoplasmic m(6)A reader YTHDF3 promotes mRNA translation. Cell Res. 2017;27(3):444–447. doi:10.1038/cr.2017.10
Medline CASGoogle Scholar
54. Xiao W, Adhikari S, Dahal U et al. Nuclear m(6)A reader YTHDC1 regulates mRNA splicing. Mol. Cell 2016;61(4):507–519. doi:10.1016/j.molcel.2016.01.012
Medline CASGoogle Scholar
55. Hsu PJ, Zhu Y, Ma H et al. Ythdc2 is an N(6)-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 2017;27(9):1115–1127. doi:10.1038/cr.2017.99
Medline CASGoogle Scholar
56. Ramesh-Kumar D, Guil S. The IGF2BP family of RNA binding proteins links epitranscriptomics to cancer. Semin. Cancer Biol. 2022;86(Pt 3):18–31. doi:10.1016/j.semcancer.2022.05.009
CASGoogle Scholar
57. Mu H, Cai S, Wang X et al. RNA binding protein IGF2BP1 meditates oxidative stress-induced granulosa cell dysfunction by regulating MDM2 mRNA stability in an m(6)A-dependent manner. Redox. Biol. 2022;57:102492. doi:10.1016/j.redox.2022.102492
CASGoogle Scholar
58. Yu D, Pan M, Li Y et al. RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m⁶A-dependent manner. J. Exp. Clin. Cancer Res. 2022;41(1):6. doi:10.1186/s13046-021-02212-1
CASGoogle Scholar
59. Zhang N, Shen Y, Li H et al. The m⁶A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability. Exp. Mol. Med. 2022;54(2):194–205. doi:10.1038/s12276-022-00735-x
CASGoogle Scholar
60. Jiang F, Tang X, Tang C et al. HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m⁶A-dependent stabilization of ILF3 mRNA. J. Hematol. Oncol. 2021;14(1):54. doi:10.1186/s13045-021-01066-6
CASGoogle Scholar
61. Alarcon CR, Goodarzi H, Lee H et al. HNRNPA2B1 is a mediator of m(6)A-dependent nuclear RNA processing events. Cell 2015;162(6):1299–1308. doi:10.1016/j.cell.2015.08.011
Medline CASGoogle Scholar
62. Huang XT, Li JH, Zhu XX et al. HNRNPC impedes m(6)A-dependent anti-metastatic alternative splicing events in pancreatic ductal adenocarcinoma. Cancer Lett. 2021;518:196–206. doi:10.1016/j.canlet.2021.07.016
CASGoogle Scholar
63. Zhou KI, Shi H, Lyu R et al. Regulation of co-transcriptional pre-mRNA splicing by m(6)A through the low-complexity protein hnRNPG. Mol. Cell 2019;76(1):70–81.e9. doi:10.1016/j.molcel.2019.07.005
CASGoogle Scholar
64. Yang F, Jin H, Que B et al. Dynamic m(6)A mRNA methylation reveals the role of METTL3-m(6)A-CDCP1 signaling axis in chemical carcinogenesis. Oncogene 2019;38(24):4755–4772. doi:10.1038/s41388-019-0755-0
Medline CASGoogle Scholar
65. Chen M, Wei L, Law CT et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology 2018;67(6):2254–2270. doi:10.1002/hep.29683
Medline CASGoogle Scholar
66. He L, Li H, Wu A et al. Functions of N6-methyladenosine and its role in cancer. Mol. Cancer 2019;18(1):176. doi:10.1186/s12943-019-1109-9
MedlineGoogle Scholar
67. Weng H, Huang H, Wu H et al. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m(6)A modification. Cell Stem Cell. 2018;22(2):191–205.e9. doi:10.1016/j.stem.2017.11.016
Medline CASGoogle Scholar
68. Liu J, Eckert MA, Harada BT et al. m(6)A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 2018;20(9):1074–1083. doi:10.1038/s41556-018-0174-4
Medline CASGoogle Scholar
69. Ma Z, Li Q, Liu P et al. METTL3 regulates m⁶A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP. Cell Biol. Int. 2020;44(12):2524–2531. doi:10.1002/cbin.11459
Medline CASGoogle Scholar
70. Liang S, Guan H, Lin X et al. METTL3 serves an oncogenic role in human ovarian cancer cells partially via the AKT signaling pathway. Oncol. Lett. 2020;19(4):3197–3204. doi:10.3892/ol.2020.11425
Medline CASGoogle Scholar
71. Jiang Y, Wan Y, Gong M et al. RNA demethylase ALKBH5 promotes ovarian carcinogenesis in a simulated tumour microenvironment through stimulating NF-kappaB pathway. J. Cell Mol. Med. 2020;24(11):6137–6148. doi:10.1111/jcmm.15228
Medline CASGoogle Scholar
72. Li J, Wu L, Pei M et al. YTHDF2, a protein repressed by miR-145, regulates proliferation, apoptosis, and migration in ovarian cancer cells. J. Ovarian Res. 2020;13(1):111. doi:10.1186/s13048-020-00717-5
MedlineGoogle Scholar
73. Li Q, Wang C, Dong W et al. WTAP facilitates progression of endometrial cancer via CAV-1/NF-kappaB axis. Cell Biol. Int. 2021;45(6):1269–1277. doi:10.1002/cbin.11570
CASGoogle Scholar
74. Zhang L, Wan Y, Zhang Z et al. FTO demethylates m⁶A modifications in HOXB13 mRNA and promotes endometrial cancer metastasis by activating the WNT signalling pathway. RNA Biol. 2021;18(9):1265–1278. doi:10.1080/15476286.2020.1841458
Google Scholar
75. Zhang L, Wan Y, Zhang Z et al. IGF2BP1 overexpression stabilizes PEG10 mRNA in an m⁶A-dependent manner and promotes endometrial cancer progression. Theranostics 2021;11(3):1100–1114. doi:10.7150/thno.49345
CASGoogle Scholar
76. Zeng C, Huang W, Li Y et al. Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J. Hematol. Oncol. 2020;13(1):117. doi:10.1186/s13045-020-00951-w
Google Scholar
77. Ni HH, Zhang L, Huang H et al. Connecting METTL3 and intratumoural CD33(+) MDSCs in predicting clinical outcome in cervical cancer. J. Transl. Med. 2020;18(1):393. doi:10.1186/s12967-020-02553-z
CASGoogle Scholar
78. Wang Q, Guo X, Li L et al. N(6)-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification. Cell Death Dis. 2020;11(10):911. doi:10.1038/s41419-020-03071-y
CASGoogle Scholar
79. Li Z, Peng Y, Li J et al. N(6)-methyladenosine regulates glycolysis of cancer cells through PDK4. Nat. Commun. 2020;11(1):2578. doi:10.1038/s41467-020-16306-5
CASGoogle Scholar
80. Du QY, Huo FC, Du WQ et al. METTL3 potentiates progression of cervical cancer by suppressing ER stress via regulating m⁶A modification of TXNDC5 mRNA. Oncogene 2022;41(39):4420–4432. doi:10.1038/s41388-022-02435-2
CASGoogle Scholar
81. Li H, Zhong Y, Cao G et al. METTL3 promotes cell cycle progression via m(6)A/YTHDF1-dependent regulation of CDC25B translation. Int. J. Biol. Sci. 2022;18(8):3223–3236. doi:10.7150/ijbs.70335
CASGoogle Scholar
82. Yu T, Wu F, Jia Y et al. RNA N(6)-methyladenosine modification mediates downregulation of NR4A1 to facilitate malignancy of cervical cancer. Cell Biosci. 2022;12(1):207. doi:10.1186/s13578-022-00937-w
CASGoogle Scholar
83. Su C, Zhang Y, Chen P et al. Methyltransferase-like 3 induces the development of cervical cancer by enhancing insulin-like growth factor 2 mRNA-binding proteins 3-mediated apoptotic chromatin condensation inducer 1 mRNA stability. Bioengineered 2022;13(3):7034–7048. doi:10.1080/21655979.2022.2044261
CASGoogle Scholar
84. Shen W, Zhu M, Wang Q et al. DARS-AS1 recruits METTL3/METTL14 to bind and enhance DARS mRNA m(6)A modification and translation for cytoprotective autophagy in cervical cancer. RNA Biol. 2022;19(1):751–763. doi:10.1080/15476286.2022.2079889 • The research describes a protective autophagy induced by the HIF1α/DARS-AS1/DARS axis in cervical cancer cells under hypoxic conditions. The article mentions a method to create a hypoxic environment (94% N2, 5% CO2, and 1% O2 were used for culturing HeLa and C33A cells for indicated time periods). The establishment of a hypoxic environment may be applicable for future experimental research.
CASGoogle Scholar
85. Li J, Xie G, Tian Y et al. RNA m(6)A methylation regulates dissemination of cancer cells by modulating expression and membrane localization of beta-catenin. Mol. Ther. 2022;30(4):1578–1596. doi:10.1016/j.ymthe.2022.01.019
CASGoogle Scholar
86. Liu P, Ju M, Zheng X et al. Methyltransferase-like 3 promotes cervical cancer metastasis by enhancing cathepsin L mRNA stability in an N6-methyladenosine-dependent manner. Cancer Sci. 2023;114(3):837–854. doi:10.1111/cas.15658
CASGoogle Scholar
87. Yu R, Wei Y, He C et al. Integrative analyses of m⁶A regulators identify that METTL3 is associated with HPV status and immunosuppressive microenvironment in HPV-related cancers. Int. J. Biol. Sci. 2022;18(9):3874–3887. doi:10.7150/ijbs.70674
Google Scholar
88. Huang C, Liang J, Lin S et al. N(6)-methyladenosine associated silencing of miR-193b promotes cervical cancer aggressiveness by targeting CCND1. Front. Oncol. 2021;11:666597. doi:10.3389/fonc.2021.666597
CASGoogle Scholar
89. Ji F, Lu Y, Chen S et al. m(6)A methyltransferase METTL3-mediated lncRNA FOXD2-AS1 promotes the tumorigenesis of cervical cancer. Mol. Ther. Oncolytics 2021;22:574–581. doi:10.1016/j.omto.2021.07.004
CASGoogle Scholar
90. Yang Z, Ma J, Han S et al. ZFAS1 exerts an oncogenic role via suppressing miR-647 in an m(6)A-dependent manner in cervical cancer. Onco. Targets Ther. 2020;13:11795–11806. doi:10.2147/OTT.S274492
CASGoogle Scholar
91. Shen G, Li F, Wang Y et al. New insights on the interaction between m(6)A modification and noncoding RNA in cervical squamous cell carcinoma. World J. Surg. Oncol. 2023;21(1):25. doi:10.1186/s12957-023-02907-z
Google Scholar
92. Shen S, Jin H, Zhang X et al. LINC00426, a novel m(6)A-regulated long noncoding RNA, induces EMT in cervical cancer by binding to ZEB1. Cell. Signal. 2023;109:110788. doi:10.1016/j.cellsig.2023.110788
CASGoogle Scholar
93. Zhao J, Lee EE, Kim J et al. Transforming activity of an oncoprotein-encoding circular RNA from human papillomavirus. Nat. Commun. 2019;10(1):2300. doi:10.1038/s41467-019-10246-5
MedlineGoogle Scholar
94. Shi J, Rui X, Han C et al. circRNF13, a novel N(6)-methyladenosine-modified circular RNA, enhances radioresistance in cervical cancer by increasing CXCL1 mRNA stability. Cell Death Discov. 2023;9(1):253. doi:10.1038/s41420-023-01557-0
CASGoogle Scholar
95. Guan Q, Lin H, Miao L et al. Functions, mechanisms, and therapeutic implications of METTL14 in human cancer. J. Hematol. Oncol. 2022;15(1):13. doi:10.1186/s13045-022-01231-5
CASGoogle Scholar
96. Geng F, Fan MJ, Li J et al. Knockdown of METTL14 inhibits the growth and invasion of cervical cancer. Transl. Cancer Res. 2019;8(6):2307–2315. doi:10.21037/tcr.2019.09.48
CASGoogle Scholar
97. Hu C, Liu T, Xu Y et al. METTL14 promotes the proliferation and migration of cervical cancer cells by up-regulating m(6)A Myc expression. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2022;38(2):131–137. Chinese.
Google Scholar
98. Xie Q, Li Z, Luo X et al. piRNA-14633 promotes cervical cancer cell malignancy in a METTL14-dependent m⁶A RNA methylation manner. J Transl Med. 2022;20(1):51. doi:10.1186/s12967-022-03257-2 • Describes a mechanism wherein piRNAs collaborate with m6A regulation in cervical cancer. Research on piRNAs in cervical cancer remains relatively limited, representing a novel perspective.
CASGoogle Scholar
99. Zhang X, Li MJ, Xia L et al. The biological function of m⁶A methyltransferase KIAA1429 and its role in human disease. Peer J. 2022;10:e14334. doi:10.7717/peerj.14334
Google Scholar
100. Ma X, Li Y, Wen J et al. m⁶A RNA methylation regulators contribute to malignant development and have a clinical prognostic effect on cervical cancer. Am. J. Transl. Res. 2020;12(12):8137–8146.
CASGoogle Scholar
101. Cai X, Chen Y, Man D et al. RBM15 promotes hepatocellular carcinoma progression by regulating N6-methyladenosine modification of YES1 mRNA in an IGF2BP1-dependent manner. Cell Death Discov. 2021;7(1):315. doi:10.1038/s41420-021-00703-w
Google Scholar
102. Zhang C, Gu L, Xiao J et al. Knockdown of RBM15 inhibits tumor progression and the JAK-STAT signaling pathway in cervical cancer. BMC Cancer 2023;23(1):684. doi:10.1186/s12885-023-11163-z
CASGoogle Scholar
103. Song Y, Wu Q. RBM15 m(6)A modification-mediated OTUB2 upregulation promotes cervical cancer progression via the AKT/mTOR signaling. Environ. Toxicol. 2023;38(9):2155–2164. doi:10.1002/tox.23852
CASGoogle Scholar
104. Nie G, Tang B, Lv M et al. HPV E6 promotes cell proliferation of cervical cancer cell by accelerating accumulation of RBM15 dependently of autophagy inhibition. Cell Biol. Int. 2023;47(8):1327–1343. doi:10.1002/cbin.12020
CASGoogle Scholar
105. Lu X, Li R, Ying Y et al. Gene signatures, immune infiltration, and drug sensitivity based on a comprehensive analysis of m⁶A RNA methylation regulators in cervical cancer. J. Transl. Med. 2022;20(1):385. doi:10.1186/s12967-022-03600-7
CASGoogle Scholar
106. Pan J, Xu L, Pan H. Development and validation of an m⁶A RNA methylation regulator-based signature for prognostic prediction in cervical squamous cell carcinoma. Front. Oncol. 2020;10:1444. doi:10.3389/fonc.2020.01444
Google Scholar
107. Lin X, Wang F, Chen J et al. N(6)-methyladenosine modification of CENPK mRNA by ZC3H13 promotes cervical cancer stemness and chemoresistance. Mil. Med. Res. 2022;9(1):19. doi:10.1186/s40779-022-00378-z
CASGoogle Scholar
108. Liu C, Li Y, Dong C et al. E6E7 regulates the HK2 expression in cervical cancer via GSK3beta/FTO signal. Arch. Biochem. Biophys. 2022;729:109389. doi:10.1016/j.abb.2022.109389
CASGoogle Scholar
109. Huang J, Yang J, Zhang Y et al. FTO promotes cervical cancer cell proliferation, colony formation, migration and invasion via the regulation of the BMP4/Hippo/YAP1/TAZ pathway. Exp. Cell Res. 2023;427(1):113585. doi:10.1016/j.yexcr.2023.113585
CASGoogle Scholar
110. Zou D, Dong L, Li C et al. The m(6)A eraser FTO facilitates proliferation and migration of human cervical cancer cells. Cancer Cell Int. 2019;19:321. doi:10.1186/s12935-019-1045-1
Medline CASGoogle Scholar
111. Wang A, Jin C, Wang Y et al. FTO promotes the progression of cervical cancer by regulating the N6-methyladenosine modification of ZEB1 and Myc. Mol. Carcinog. 2023;62(8):1228–1237. doi:10.1002/mc.23559
CASGoogle Scholar
112. Wang T, Li W, Ye B et al. FTO-stabilized lncRNA HOXC13-AS epigenetically upregulated FZD6 and activated Wnt/beta-catenin signaling to drive cervical cancer proliferation, invasion, and EMT. J. BUON 2021;26(4):1279–1291. https://www.jbuon.com/archive/26-4-1279.pdf117
Google Scholar
113. Zhou S, Bai ZL, Xia D et al. FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting beta-catenin through mRNA demethylation. Mol. Carcinog. 2018;57(5):590–597. doi:10.1002/mc.22782
Medline CASGoogle Scholar
114. Qu J, Yan H, Hou Y et al. RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential. J. Hematol. Oncol. 2022;15(1):8. doi:10.1186/s13045-022-01224-4
CASGoogle Scholar
115. Huo FC, Zhu ZM, Du WQ et al. HPV E7-drived ALKBH5 promotes cervical cancer progression by modulating m⁶A modification of PAK5. Pharmacol. Res. 2023;195:106863. doi:10.1016/j.phrs.2023.106863
CASGoogle Scholar
116. Zhen L, Pan W. ALKBH5 inhibits the SIRT3/ACC1 axis to regulate fatty acid metabolism via an m⁶A-IGF2BP1-dependent manner in cervical squamous cell carcinoma. Clin. Exp. Pharmacol. Physiol. 2023;50(5):380–392. doi:10.1111/1440-1681.13754
CASGoogle Scholar
117. Wang X, Zhang J, Wang Y. Long noncoding RNA GAS5-AS1 suppresses growth and metastasis of cervical cancer by increasing GAS5 stability. Am. J. Transl. Res. 2019;11(8):4909–4921. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731424/
CASGoogle Scholar
118. Chen Z, Zhong X, Xia M et al. The roles and mechanisms of the m⁶A reader protein YTHDF1 in tumor biology and human diseases. Mol. Ther. Nucleic Acids. 2021;26:1270–1279. doi:10.1016/j.omtn.2021.10.023
CASGoogle Scholar
119. Wang H, Luo Q, Kang J et al. YTHDF1 aggravates the progression of cervical cancer through m(6)A-mediated up-regulation of RANBP2. Front. Oncol. 2021;11:650383. doi:10.3389/fonc.2021.650383
CASGoogle Scholar
120. Wang JY, Lu AQ. The biological function of m⁶A reader YTHDF2 and its role in human disease. Cancer Cell Int. 2021;21(1):109. doi:10.1186/s12935-021-01807-0
Google Scholar
121. Liang L, Zhu Y, Li J et al. ALKBH5-mediated m⁶A modification of circCCDC134 facilitates cervical cancer metastasis by enhancing HIF1A transcription. J. Exp. Clin. Cancer Res. 2022;41(1):261. doi:10.1186/s13046-022-02462-7
CASGoogle Scholar
122. Wu M, Chen G, Liao X et al. YTHDF2 interference suppresses the EMT of cervical cancer cells and enhances cisplatin chemosensitivity by regulating AXIN1. Drug Dev. Res. 2022;83(5):1190–1200. doi:10.1002/ddr.21942
Medline CASGoogle Scholar
123. Shi H, Wang X, Lu Z et al. YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Res. 2017;27(3):315–328. doi:10.1038/cr.2017.15
Medline CASGoogle Scholar
124. Du H, Zou NY, Zuo HL et al. YTHDF3 mediates HNF1alpha regulation of cervical cancer radio-resistance by promoting RAD51D translation in an m⁶A-dependent manner. FEBS J. 2023;290(7):1920–1935. doi:10.1111/febs.16681
CASGoogle Scholar
125. Condic M, Ralser DJ, Klumper N et al. Comprehensive analysis of N6-methyladenosine (m⁶A) writers, erasers, and readers in cervical cancer. Int. J. Mol. Sci. 2022;23(13):7165. doi:10.3390/ijms23137165
CASGoogle Scholar
126. Ma C, Liao S, Zhu Z. Crystal structure of human YTHDC2 YTH domain. Biochem. Biophys. Res. Commun. 2019;518(4):678–684. doi:10.1016/j.bbrc.2019.08.107
CASGoogle Scholar
127. Zhang C, Guo C, Li Y et al. The role of YTH domain containing 2 in epigenetic modification and immune infiltration of pan-cancer. J. Cell. Mol. Med. 2021;25(18):8615–8627. doi:10.1111/jcmm.16818
CASGoogle Scholar
128. Sun CY, Cao D, Du BB et al. The role of Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) as m(6)A readers in cancer. Int. J. Biol. Sci. 2022;18(7):2744–2758. doi:10.7150/ijbs.70458
CASGoogle Scholar
129. Wang L, Zhan G, Maimaitiyiming Y et al. m(6)A modification confers thermal vulnerability to HPV E7 oncotranscripts via reverse regulation of its reader protein IGF2BP1 upon heat stress. Cell Rep. 2022;41(4):111546. doi:10.1016/j.celrep.2022.111546
Medline CASGoogle Scholar
130. Wang J, Chen L, Qiang P. The role of IGF2BP2, an m⁶A reader gene, in human metabolic diseases and cancers. Cancer Cell Int. 2021;21(1):99. doi:10.1186/s12935-021-01799-x • This research reports a novel regulatory mechanism: heat treatment can suppress the oncogenic potential of HPV-positive cervical cancer cells by degrading the E7-IGF2BP1 complex.
Google Scholar
131. Hu C, Liu T, Han C et al. HPV E6/E7 promotes aerobic glycolysis in cervical cancer by regulating IGF2BP2 to stabilize m(6)A-MYC expression. Int. J. Biol. Sci. 2022;18(2):507–521. doi:10.7150/ijbs.67770 •• Reports that HPV E6/E7 can promote the progression of cervical cancer by facilitating glycolysis through the IGF2BP2/A-MYC pathway. The study integrates the high-risk factor HPV with metabolism and epigenetics to explore the mechanisms in cervical cancer, presenting a research approach worthy of emulation.
Medline CASGoogle Scholar
132. Ji F, Lu Y, Chen S et al. IGF2BP2-modified circular RNA circARHGAP12 promotes cervical cancer progression by interacting m(6)A/FOXM1 manner. Cell Death Discov. 2021;7(1):215. doi:10.1038/s41420-021-00595-w
CASGoogle Scholar
133. Liu X, Chen J, Chen W et al. Targeting IGF2BP3 in Cancer. Int.J. Mol. Sci. 2023;24(11):9423. doi:10.3390/ijms24119423
CASGoogle Scholar
134. Zhang Y, Wang D, Wu D et al. Long noncoding RNA KCNMB2-AS1 stabilized by N(6)-methyladenosine modification promotes cervical cancer growth through acting as a competing endogenous RNA. Cell Transplant. 2020;29:963689720964382. doi:10.1177/0963689720964382
Google Scholar
135. Zhang W, Xiao P, Tang J et al. m⁶A regulator-mediated tumour infiltration and methylation modification in cervical cancer microenvironment. Front. Immunol. 2022;13:888650. doi:10.3389/fimmu.2022.888650
CASGoogle Scholar
136. Chen D, Guo W, Yu H et al. Construction and validation of prognostic prediction established on N6-methyladenosine related genes in cervical squamous cell carcinoma. Transl Cancer Res. 2022;11(9):3064–3079. doi:10.21037/tcr-22-881
CASGoogle Scholar
137. Ji H, Zhang JA, Liu H et al. Comprehensive characterization of tumor microenvironment and m⁶A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer. Front. Immunol. 2022;13:976107. doi:10.3389/fimmu.2022.976107
CASGoogle Scholar
138. Guo Y, Bai Y, Wang L et al. The significance of m⁶A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer. Medicine (Baltimore) 2022;101(26):e29818. doi:10.1097/MD.0000000000029818
CASGoogle Scholar
139. Wang S, Ding B, Wang S et al. Gene signature of m(6)A RNA regulators in diagnosis, prognosis, treatment, and immune microenvironment for cervical cancer. Sci Rep. 2022;12(1):17667. doi:10.1038/s41598-022-22211-2
CASGoogle Scholar
140. Zhang H, Kong W, Zhao X et al. N6-Methyladenosine-Related lncRNAs as potential biomarkers for predicting prognoses and immune responses in patients with cervical cancer. BMC Genom Data. 2022;23(1):8. doi:10.1186/s12863-022-01024-2
Google Scholar
141. Jia H, Hao S, Cao M et al. m(6)A-Related lncRNAs Are Potential Prognostic Biomarkers of Cervical Cancer and Affect Immune Infiltration. Dis. Markers 2022;2022:8700372. doi:10.1155/2022/8700372
Google Scholar
142. Jia H, Cao M, Hao S et al. Prediction of prognosis, immune infiltration and immunotherapy response with N6-methyladenosine-related lncRNA clustering patterns in cervical cancer. Sci Rep. 2022;12(1):17256. doi:10.1038/s41598-022-20162-2
CASGoogle Scholar
143. Liu X, Zhang W, Wan J et al. Landscape and Construction of a Novel N6-methyladenosine-related LncRNAs in Cervical Cancer. Reprod Sci. 2023;30(3):903–913. doi:10.1007/s43032-022-01074-y
CASGoogle Scholar
144. Gu R, Liu M, Lin P et al. Correlation analysis of Poor Prognosis and Immunotherapy of lncRNAs Related with m (6)A Modification in Cervical Cancer. Sichuan Da Xue Xue Bao Yi Xue Ban. 2022;53(4):626–636. doi:10.12182/20220760504. Chinese.
Google Scholar
145. Shi YL, Liu MB, Wu HT et al. GLTP Is a Potential Prognostic Biomarker and Correlates with Immunotherapy Efficacy in Cervical Cancer. Dis. Markers 2022;2022:9109365. doi:10.1155/2022/9109365
Google Scholar
146. Lin Z, Zou J, Sui X et al. Necroptosis-related lncRNA signature predicts prognosis and immune response for cervical squamous cell carcinoma and endocervical adenocarcinomas. Sci Rep. 2022;12(1):16285. doi:10.1038/s41598-022-20858-5
CASGoogle Scholar
147. Zou J, Lin Z, Jiao W et al. A multi-omics-based investigation of the prognostic and immunological impact of necroptosis-related mRNA in patients with cervical squamous carcinoma and adenocarcinoma. Sci Rep. 2022;12(1):16773. doi:10.1038/s41598-022-20566-0
CASGoogle Scholar
148. Chen Z, Ling K, Zhu Y et al. circ0000069 promotes cervical cancer cell proliferation and migration by inhibiting miR-4426. Biochem. Biophys. Res. Commun. 2021;551:114–120. doi:10.1016/j.bbrc.2021.03.020
CASGoogle Scholar
149. Liu L, Li L, Zu W et al. PIWI-interacting RNA-17458 is oncogenic and a potential therapeutic target in cervical cancer. J Cancer. 2023;14(9):1648–1659. doi:10.7150/jca.83446
CASGoogle Scholar
150. Wang Y, Mao Y, Wang C et al. RNA methylation-related genes of m⁶A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer. Ann. Med. 2023;55(1):2190618. doi:10.1080/07853890.2023.2190618
Google Scholar
151. Meng Q, Schatten H, Zhou Q et al. Crosstalk between m⁶A and coding/noncoding RNA in cancer and detection methods of m⁶A modification residues. Aging (Albany NY). 2023;15(13):6577–6619. doi:10.18632/aging.204836
CASGoogle Scholar
152. Wang Y, Jia G. Detection methods of epitranscriptomic mark N6-methyladenosine. Essays Biochem. 2020;64(6):967–979. doi:10.1042/EBC20200039
CASGoogle Scholar
153. Liu XM, Zhou J, Mao Y et al. Programmable RNA N(6)-methyladenosine editing by CRISPR-Cas9 conjugates. Nat Chem Biol. 2019;15(9):865–871. doi:10.1038/s41589-019-0327-1 • The study employed CRISPR-Cas9 for m6A editing, enabling site-specific demethylation. This technology can be utilized in future studies of m6A modification.
CASGoogle Scholar
154. Chen M, Wong CM. The emerging roles of N6-methyladenosine (m⁶A) deregulation in liver carcinogenesis. Mol Cancer. 2020;19(1):44. doi:10.1186/s12943-020-01172-y
Medline CASGoogle Scholar
155. Li X, Ma S, Deng Y et al. Targeting the RNA m(6)A modification for cancer immunotherapy. Mol Cancer. 2022;21(1):76. doi:10.1186/s12943-022-01558-0
CASGoogle Scholar
156. Rauch S, He C, Dickinson BC. Targeted m(6)A reader proteins to study epitranscriptomic regulation of single RNAs. J. Am. Chem. Soc. 2018;140(38):11974–11981. doi:10.1021/jacs.8b05012
CASGoogle Scholar
157. Selberg S, Blokhina D, Aatonen M et al. Discovery of small molecules that activate rna methylation through cooperative binding to the METTL3-14-WTAP complex active site. Cell Rep. 2019;26(13):3762–3771.e5. doi:10.1016/j.celrep.2019.02.100
CASGoogle Scholar
158. Bedi RK, Huang D, Eberle SA et al. Small-Molecule Inhibitors of METTL3, the Major Human Epitranscriptomic Writer. ChemMedChem. 2020;15(9):744–748. doi:10.1002/cmdc.202000011
CASGoogle Scholar
159. Yankova E, Blackaby W, Albertella M et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 2021;593(7860):597–601. doi:10.1038/s41586-021-03536-w
Medline CASGoogle Scholar
160. Huang Y, Su R, Sheng Y et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell. 2019;35(4):677–691.e10. doi:10.1016/j.ccell.2019.03.006
Medline CASGoogle Scholar
161. Zhang Y, Li QN, Zhou K et al. Identification of specific N(6)-methyladenosine RNA demethylase FTO inhibitors by single-quantum-dot-based FRET nanosensors. Anal. Chem. 2020;92(20):13936–13944. doi:10.1021/acs.analchem.0c02828
CASGoogle Scholar
162. Peng S, Xiao W, Ju D et al. Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1. Sci. Transl. Med. 2019;11(488). doi:10.1126/scitranslmed.aau7116
Google Scholar
163. Selberg S, Seli N, Kankuri E et al. Rational design of novel anticancer small-molecule RNA m⁶A Demethylase ALKBH5 inhibitors. ACS Omega 2021;6(20):13310–13320. doi:10.1021/acsomega.1c01289 •• The research introduces a high-throughput screening method for ALKBH5 inhibitors, employing computer modeling to select target compounds from thousands of compounds. This provides an efficient approach for screening m6A regulatory agonists/inhibitors, which may be applicable for future scientific research.
CASGoogle Scholar
164. Li N, Kang Y, Wang L et al. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc. Natl Acad. Sci. USA 2020;117(33):20159–20170. doi:10.1073/pnas.1918986117
CASGoogle Scholar
165. Yu H, Yang X, Tang J et al. ALKBH5 inhibited cell proliferation and sensitized bladder cancer cells to cisplatin by m⁶A-CK2alpha-mediated glycolysis. Mol. Ther. Nucleic Acids. 2021;23:27–41. doi:10.1016/j.omtn.2020.10.031
Medline CASGoogle Scholar
166. Chen H, Xiang Y, Yin Y et al. The m⁶A methyltransferase METTL3 regulates autophagy and sensitivity to cisplatin by targeting ATG5 in seminoma. Transl. Androl. Urol. 2021;10(4):1711–1722. doi:10.21037/tau-20-1411
Google Scholar
167. Xiao P, Liu YK, Han W et al. Exosomal delivery of FTO confers gefitinib resistance to recipient cells through ABCC10 Regulation in an m⁶A-dependent manner. Mol. Cancer Res. 2021;19(4):726–738. doi:10.1158/1541-7786.MCR-20-0541
CASGoogle Scholar
168. DiNardo CD, Jonas BA, Pullarkat V et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 2020;383(7):617–629. doi:10.1056/NEJMoa2012971
Medline CASGoogle Scholar

Ahead of Print

Metrics

Downloaded 35 times

History

Received 3 January 2024

Accepted 27 March 2024

Published online 19 April 2024

Information

Keywords

Author contributions

Wrote the manuscript: J Hu. Review and editing: S Wang, X Li

Financial disclosure

This work was supported by the Fundamental Research Funds for the Central Universities (2242023K40023), Opening Foundation of Jiangsu Provincial Health Development Research Center (JSHD2022056 & JSHD202305), Scientific Research Project of Jiangsu Provincial Health Commission (Z2019009), Natural Science Foundation for Colleges and Universities of Jiangsu Province (22KJB330004) and Major Project of Jiangsu Health Vocational College (JKA202202).

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

PDF download

A comprehensive review of m6A research in cervical cancer

Abstract

Tweetable abstract

References

A comprehensive review of m⁶A research in cervical cancer